0000899243-22-009061.txt : 20220303 0000899243-22-009061.hdr.sgml : 20220303 20220303161552 ACCESSION NUMBER: 0000899243-22-009061 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220301 FILED AS OF DATE: 20220303 DATE AS OF CHANGE: 20220303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MAHAFFY PATRICK J CENTRAL INDEX KEY: 0001266569 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 22708931 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 5500 FLATIRON PARKWAY, SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-01 0 0001466301 Clovis Oncology, Inc. CLVS 0001266569 MAHAFFY PATRICK J C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 1 1 0 0 See Remarks Stock Option (right to buy) 1.95 2022-03-01 4 A 0 220000 0.00 A 2032-03-01 Common Stock 220000 220000 D Stock Option (right to buy) 1.95 2022-03-01 4 A 0 80000 0.00 A 2032-03-01 Common Stock 80000 80000 D Stock Option (right to buy) 1.95 2022-03-01 4 A 0 80000 0.00 A 2032-03-01 Common Stock 80000 80000 D The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021. The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024. President and Chief Executive Officer /s/ Patrick Mahaffy 2022-03-02